Cervical cancer rates are on the rise among younger women, owing in part to a lack of screening and prevention.

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Current guidelines lack consensus and rely on lower-quality evidence, according to the author of new research.

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

While the report shows continued progress on many fronts, certain areas remain of “significant concern,” Dr. Joshua Strauss, ...

The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Prevent cervical cancer with screenings, HPV vaccine, and healthy habits. Early detection saves lives. Empower yourself for a ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Japan approves Tivdak, the first ADC for cervical cancer ... TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical cancer who were previously treated with chemotherapy.